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Psoriasis is the most common and chronic skin disease that affects individuals from every
age group. The rate of psoriasis is increasing over the time in both developed and
developing countries. Studies have revealed the possibility of association of psoriasis with
skin cancers, particularly non-melanoma skin cancers (NMSC), which, include basal cell
carcinoma and cutaneous squamous cell carcinoma (cSCC). There is a need to analyze
the disease at molecular level to propose potential biomarkers and therapeutic targets in
comparison to cSCC. Therefore, the second analyzed disease of this study is cSCC. It is
the second most common prevalent skin cancer all over the world with the potential to
metastasize and recur. There is an urge to validate the proposed biomarkers and discover
new potential biomarkers as well. In order to achieve the goals and objectives of the study,
microarray and RNA-sequencing data analyses were performed followed by network
analysis. Afterwards, quantitative systems biology was implemented to analyze the results
at a holistic level. The aim was to predict the molecular patterns that can lead psoriasis to
cancer. The current study proposed potential biomarkers and therapeutic targets for
psoriasis and cSCC. IL-17 signaling pathway is also identified as significant pathway in
both diseases. Moreover, the current study proposed that autoimmune pathology,
neutrophil recruitment, and immunity to extracellular pathogens are sensitive towards
MAPKs (MAPK13 and MAPK14) and genes for AP-1 (FOSL1 and FOS). Therefore, these
genes should be further studied in gene knock down based studies as they may play
significant role in leading psoriasis towards cancer.
Keywords: microarray data analysis, RNA-seq data analysis, psoriasis, cutaneous squamous cell carcinoma,
pathway analysis, biomarkers, therapeutic target, differentially expressed genes
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INTRODUCTION
Psoriasis is one of the most common and chronic skin diseases
(1). It is characterized by rough scales on the skin. It could appear
on any part of the body and it affects both children and adults
(1). About 2-3% individuals are affected by psoriasis worldwide,
that means more than 125 million people suffer from psoriasis
(2). Males and females are equally targeted by psoriasis i.e., male
to female ratio is 1:1. The usual onset of the disease is reported to
be between 18 and 39 years, or between 50 and 69 years (2). The
onset age of the disease is associated with genetic and epigenetic
factors (2). The incidence rate of psoriasis is also observed to
increase with time (3). The pathogenesis of psoriasis is still
unclear and there are two hypotheses regarding it (4). The first
hypothesis assumes that in psoriasis the immune system of the
body appears to be hyperactive to an extent that it attacks itself
(4); which is the characteristic of the autoimmune disease.
Therefore, psoriasis shows characteristics of an autoimmune
disorder (4, 5). According to the second hypothesis, the life
cycle of the skin cells speeds up in psoriasis from 28 days to 3-6
days, which results in excessive cell growth (4, 6). It eventually
causes the formation of dead skin cells. Despite of being shed off,
these dead cells accumulate at the surface of the skin and form
lesions and patches (6). Frequently, red patches or dry scales
appear on elbows, knees, and scalps (7). In an individual’s
lifetime psoriasis often occur repeatedly (7). The exact cause
and cure of psoriasis has not yet been discovered. However,
multiple factors including environmental & genetic factors and
immune system of the body are considered for it (8). It is
predicted that environmental factors like cold and dry weather
could trigger the symptoms of psoriasis (9). Moreover, the
symptoms of psoriasis could appear after certain infections like
strep throat and even in stress (9). Both genetic and epigenetic
factors play the substantial role in the formation and
exacerbation of the symptoms of the disease (10). Genetic risk
factors are HLA-Cw6, mutations in CARD14 (10). CARD14 is
caspase recruitment domain family member 14 gene. Obesity,
stress, smoking, alcohol consumption, HIV infection, and certain
medications serve as the epigenetic factors of the disease (11).
Association of psoriasis with other comorbidities, like
cardiovascular diseases, diabetes, and metabolic syndrome, has
been observed (12). An interesting study (13) was conducted for
analyzing the implication of cutaneous squamous cell carcinoma
(cSCC) antigen with psoriasis. This study was based on the fact that
serum (fluid after blood coagulation) examination of psoriasis
patients always revealed the presence of cSCC antigen. The study
confirmed the concentration and over-expression of cSCC antigen
in psoriatic lesions. A transcriptome level analysis was performed to
reveal common patterns in cSCC and psoriasis (14). In this
experiment, expression levels in cSCC were compared with
multiple cutaneous disorders by performing microarray analysis.
The comparison of cSCC with psoriasis (psoriasis vulgaris) revealed
some genes depicting same expression behavior by up regulation in
both disease states of cSCC and psoriasis. Subsequently, RT (real
time) reverse transcription PCR (polymerase chain reaction) along
with immunohistochemistry were also performed to validate the
differential expression of genes attained after comparison in both
disease states of cSCC and psoriasis. The common over-expressed
genes found in both cSCC and psoriasis were: DEFB4 (defensin B4),
SERPINB3, STAT1, K16 (keratin 16), WNT5A, and CEACAM5. In
another study (15), histopathological examination of a biopsy of a
psoriasis patient revealed the development of cSCC. That patient
showed negative family history regarding psoriasis and only
received homeopathic treatment for psoriasis.
Studies have revealed the possibility of association of psoriasis
with skin cancers, particularly non melanoma skin cancer
(NMSC), which include basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC) (12, 16). A cohort study
(1988-2011) (16) was conducted for estimating malignancy
rates in psoriasis patients treated with systemic therapy. This
study reported that there exists a higher rate of developing cSCC
among psoriasis patients who were treated with biologics as a
treatment. The speculation regarding the association of psoriasis
with NMSC was built on the fact that immunosuppressors and
ultraviolet phototherapy are used for treating psoriasis (12, 16).
Moreover, the long-lasting inflammatory nature of psoriasis
might also escalate the threat of NMSC in psoriasis patients
(12). That is why, the second studied disease in this study
is cSCC.
Most commonly, skin cancer is characterized by the abnormal
growths of the skin (17). A sore that does not heal or takes time
to heal could also be the indicator of skin cancer. Symptoms of
skin cancer vary differently for its different subtypes. For
instance, it could appear as small, smooth lumps. However, in
some cases skin cancer appears as scaly, hard lumps that often
bleed (17). Skin cancer is divided into melanoma and non-
melanoma categories. Basal Cell Carcinoma (BCC) and
Squamous Cell Carcinoma (SCC) set up non-melanoma skin
cancer (17, 18). Squamous Cell Carcinoma is also known as
cutaneous squamous cell carcinoma (cSCC). cSCC is the second
most prevalent non-melanoma skin cancer (19, 20) and has the
potential to recur/revert (19). It is mostly reported to appear in
the Caucasian population (21). Furthermore, cSCC also accounts
for about 20% of all the cutaneous cancers (19, 20, 22, 23).
Regardless of the low occurrence of cutaneous SCC, it is
responsible for the majority of the metastasis in disease,
eventually causing deaths (24). It is stated to be counted in the
list of topmost expensive cancers in the US (United States) (24).
The prevalence rate of the cSCC is also vastly growing annually
(25). Cutaneous SCC is caused by malignant multiplication and
spread of epidermal keratinocytes (26). Often it appears on the
sun exposed areas of the body; like face, head, hands, dorsal side
of forearms and neck regions (17), and is more prevalent in
elderly males (26). It has also been observed and reported that
the particular rough patches resulted from sun exposure (aka
Actinic Keratosis) also transform or lead to cSCC (17, 26, 27).
Light skin tone, ultraviolet radiations, arsenic compounds, and
immunosuppression are the reported risk factors and are found
to increase the likelihood of developing cSCC (28). Some of the
common pathological and clinical factors for the examination of
the disease are age, gender, ethnicity, tumor size, histology, organ
transplantation, psoriasis, leukemia, history of previously injured
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skin & nodal metastasis (29). Along with patient’s characteristics,
tumor site & size, tumor depth, and histologic features accounts
for recurrence and metastasis risks of cSCC (26). Genes which
are reported to be frequently mutated in cSCC are TP53,
CDKN2A, Ras, and NOTCH1 (20).
With the increasing annual incidence of psoriasis and cSCC,
there is a great urge to comprehend and compare the diseases at
the molecular level by interpreting the genomic data. There is a
need to validate known biomarkers of psoriasis and cSCC
through high throughput data. Moreover, common therapeutic
target for both the diseases is not yet discovered. It has also been
discussed that prolonged psoriasis could lead to cSCC (15).
According to our understanding, the association of both the
diseases has not been comparatively analyzed at molecular level
in detail. In the current study, microarray and RNA-seq data
analyses have been performed on the publicly available datasets
of both psoriasis and cSCC to reveal the common and
uncommon patterns in both the diseases.
MATERIALS AND METHODS
The workflow to identify potential biomarkers, therapeutic
targets, and to comprehend the association between cSCC and
psoriasis, is given in Figure 1 and described below in detail.
Datasets Inclusion Criteria
Publicly available datasets of human origin, free from drugs, cell
lines, and mutations, were selected from EMBL-EBI (https://
www.ebi.ac.uk/) and GEO (https://www.ncbi.nlm.nih.gov/geo/)
databases against query words like, psoriasis and cutaneous
squamous cell carcinoma (cSCC). Additionally, to make the
statistical analysis significant, those datasets with enough
number of samples were selected. The Table 1 shows the
details of analyzed datasets of both the diseases.
A total of 3 datasets were analyzed for microarray data
analysis of cSCC, as given in Table 1. Two of these datasets,
with accession numbers E-GEOD-32868 and E-GEOD-34536,
are of miRNA type, containing 4 and 14 samples, respectively.
The third dataset, with accession number E-GEOD-42677 is of
mRNA type, containing 20 samples.
For microarray data analysis of psoriasis, a total of 5 datasets
were analyzed, as given in Table 1. All these datasets are of
mRNA type, with accession numbers E-GEOD-75343, E-GEOD-
50790, E-GEOD-41664, E-GEOD-34248 and E-GEOD-13355,
containing 45, 8, 76, 28 and 180 samples, respectively.
Datasets for RNA-seq analysis of both the diseases are given
in Table 1. All datasets are of mRNA type and from illumina
platform. Two datasets were analyzed for cSCC, with accession
numbers E-MTAB-5678 and GSE84293, containing 9 and 15
samples, respectively. Two datasets were analyzed for psoriasis,
FIGURE 1 | General Workflow of the Project. In order to achieve the aims and objectives of this study, integrated data analysis of microarray and RNA-seq were
performed for cSCC and psoriasis. From differential expression analysis, common DEGs between psoriasis and cSCC were identified that are proposed as potential
biomarkers and therapeutic targets for both the diseases. Pathway analysis was then performed to analyze the disrupted pathways and their possible relation with
the disease. The significant pathways (at p-value <= 0.05) from every dataset were then compared for common pathway. As a result of this comparison, one
common pathway, named IL-17 signaling pathway, was identified. Afterwards, quantitative systems biology was implemented to analyze the results at a holistic level.
A sub-section of complete IL-17 pathway was modeled by using SimBiology application in Matlab (30). The average expressions values of DEGs that were present in
the pathway were calculated for microarray datasets of psoriasis and cSCC. The model was then simulated by adding the average expression values. After
simulation of the model, sensitivity analysis was performed to analyze the response of the biological processes to model quantities (DEGs and genes). Sensitivity
analysis of the biological processes of both psoriasis and cSCC revealed significant genes that might lead psoriasis to cancer and could also be proposed as
potential biomarkers and therapeutic targets of both the diseases.
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with accession numbers E-GEOD-41745 and E-GEOD-67785,
containing 6 and 28 samples, respectively.
Differential Expression Analysis
Microarray Data Analysis
Microarray data analysis was performed in R (version of 3.5.1). A
published maEndToEnd pipeline (31) for Affymetrix platform,
was used for microarray datasets of mRNA type. The quality
control (QC) of the data was performed by data visualization and
filtering techniques which include box plot, principal component
analysis (PCA) plot, relative log expression (RLE) plot, and
Heatmap clustering analysis. PCA and heatmap clustering
analysis were performed and plotted to visualize the
logarithmic transformations by using Bioconductor R packages
(32, 33). Afterwards, the probes having low intensity along with
the low variance were removed to avoid noise in data. Then to
normalize gene expression intensities quantile normalization
method (34, 35) was used. The differentially expressed genes
(DEGs) were identified by fitting linear model in disease samples
relative to control/normal (defined groups) by using the R
package limma (36). The R package limma has linear model
features and is specifically designed for comparative analysis
between various experimental groups. Empirical bayes variance
moderation method was implemented to the data by using
eBayes function to generate the statistical significance values
for DEGs (32).
The two selected microarray datasets of cSCC (E-GEOD-
32868 and E-GEOD-34536) are of miRNA type. The dataset with
accession number E-GEOD-32868 is of Affymetrix platform. The
analysis of that dataset was performed by modifying the
maendtoend pipeline (31) by omitting the ‘Annotation step’, as
annotation is not required for microarray data analysis of
miRNAs. The dataset with accession number E-GEOD-34536
is from Agilent platform. The analysis of that dataset was
performed by AgiMicroRna package (37) in R. The
AgiMicroRna package integrates the RMA (robust multiarray
average) algorithm for preprocessing and differential expression
computation of Agilent miRNA data. The RMA algorithm
implements the linear model from the R package limma (36).
After obtaining miRNAs, their target genes were extracted from
miRWalk (38). miRWalk is a publicly available database of
miRNAs targets, which integrates multiple prediction
programs in a user-friendly interface. For extraction of target
genes, p-value was set to < 0.005 and all the prediction programs
were selected.
RNA-Sequencing Data Analysis
A published ‘new Tuxedo’ protocol (39) for RNA-seq data
analysis was followed in this study. A Unix based workstation
was used for this analysis. To address the issues regarding raw
data reads of RNA-seq data, like adapter contamination, over-
represented or inaccurately represented sequences and base
correction etc., fastp (40) preprocessor was used. After
preprocessing, the pre-processed reads were aligned to the
genome by using Hisat2 (41) aligner. Afterwards, StringTie
(42) was used to assemble complex aligned reads. Transcripts
were assembled individually for each sample of the dataset being
analyzed. After successful assembling, the collective merging of
TABLE 1 | Microarray and RNA-seq datasets.




Affymetrix miRNA cSCC 4 USA
2 E-GEOD-34536 Homo
Sapiens
Agilent miRNA cSCC 14 Germany
3 E-GEOD-42677 Homo
Sapiens
Affymetrix mRNA cSCC 20 USA
4 E-GEOD-75343 Homo
Sapiens
Affymetrix mRNA Psoriasis 45 USA
5 E-GEOD-50790 Homo
Sapiens
Affymetrix mRNA Psoriasis 8 USA
6 E-GEOD-41664 Homo
Sapiens
Affymetrix mRNA Psoriasis 76 USA
7 E-GEOD-34248 Homo
Sapiens
Affymetrix mRNA Psoriasis 28 USA
8 E-GEOD-13355 Homo
Sapiens




Illumina mRNA Psoriasis 6 USA
2 E-GEOD-67785 Homo
Sapiens
Illumina mRNA Psoriasis 28 USA
3 E-MTAB-5678 Homo
Sapiens
Illumina mRNA cSCC 9 UK
4 GSE84293 Homo
Sapiens
Illumina mRNA cSCC 15 USA
The First eight rows show the information regarding microarray datasets of both the diseases, while, the information regarding RNA-seq datasets is given in last four rows. All the selected
datasets for RNA-seq analysis have single end (SE) data, except for the dataset E-MTAB-5678, which contains paired end (PE) data.
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transcripts from all samples was also performed by using
StringTie. In order to match the output from StringTie with
reference file, a specialized program named gffcompare (http://
ccb.jhu.edu/software/stringtie/gff.shtml) was used. The aligned
and assembled reads were then subjected to quantification by
using StringTie. Quantification refers to the computation of
abundances of mapped assembled transcripts. Finally, Ballgown
package (43) of R was used for computing differential expression.
Parameters for Identifying DEGs
In this study, a gene is identified as differentially expressed when
it crossed both the defined thresholds of p-value and fold change.
Stringent thresholds of p-value (p-value < 0.005) and fold change
(-1 > Log2FC | Log2FC > +1) were used between groups of normal
and disease phenotypes. Less stringent thresholds of p-value (p-
value < 0.05) and fold change (-0.5 > Log2FC | Log2FC > +0.5)
were used when the comparisons were made between subtypes of
a disease, and between non-lesional and normal phenotypes. Our
reason for this is that the non-lesional skin of the psoriasis
patients behave normally, and the differential expression
between subtypes of a disease would be smaller as compared to
the healthy counterparts. The DEGs were visually analyzed by
using the R package EnhancedVolcano (44).
Pathway Analysis
Pathway analysis was performed to analyze the disrupted
pathways and their possible relation with both diseases, based
on the number of DEGs. The enriched pathways of DEGs were
identified using Enrichr (45) database and KEGG based
pathways were identified. The significant pathways (at p-value
<= 0.05) from every dataset were then compared for common
pathway. As a result of this comparison, one common pathway,
named IL-17 signaling pathway, was identified (given
in Table 4).
Quantitative Systems Biology
IL-17 signaling pathway was selected for further analysis, as it
was common in both psoriasis and cSCC datasets (The KEGG
IL-17 signaling pathway - Homo sapiens is provided in
Supplementary File 1). The average expression values of the
DEGs present in the IL-17 pathway were calculated for both
psoriasis and cSCC microarray datasets, as given in Table 5.
Quantitative systems biology was implemented by using
‘SimBiology’ application in Matlab (30). A sub-section of
complete IL-17 signaling pathway was modeled in Matlab for
analyzing the sensitivities of autoimmune pathology (AP),
neutrophil recruitment (NR), and immunity to extracellular
pathogens (IEP) towards DEGs, by using block diagram editor
in SimBiology. The species were used as biological entities
(genes/biological processes) in the model. The activation and
inhibition reactions were then added among species in
accordance with the IL-17 signaling pathway. The model was
then simulated by adding the average expression values to the
species (genes) as initial state values. The genes that were not
differentially expressed in the pathway were set to 0.5 as initial
state value. The reason we have proposed that value to be at 0.5
because it resides between the values of 0 and 1, which are the
minimum and maximum values that can be settled for these
genes. The biological processes being analyzed in the model were
autoimmune pathology, neutrophil recruitment, and immunity
to extracellular pathogens. The initial state values of these
biological processes were set at zero because we wanted to
analyze the response of these biological processes to model
quantities (DEGs and other). Once all the initial state values
were set, the model was simulated separately for DEGs in
psoriasis and cSCC by using ‘SimBiology’ application in
Matlab (30). As a result of simulations, graphs were generated
(given in Figure 5).
After simulating the model, sensitivity analysis (46) was
performed. We wanted to analyze the assumptions about the
influences of model entities and reactions on overall model
response. Sensitivity of biological processes (autoimmune
pathology, neutrophil recruitment, and immunity to
extracellular pathogens) in a model were analyzed against
genes. All the genes were taken as input genes, whereas
biological processes were taken as output. The sensitivity
graphs were then generated for further analysis (given in
Figures 6 and 7).
RESULTS
Differential Expression Analysis
Microarray Data Analysis of Psoriasis
The microarray data analysis was performed on the selected
psoriasis datasets using the methodology described
comprehensively in the section “Methods”. In the current
study, five mRNA type microarray data sets were selected for
psoriasis as given in Table 1. For two datasets of psoriasis (E-
GEOD-13355 & E-GEOD-75343), three phenotypic subgroups
were available, which were used to draw comparison between
three groups including lesional & non-lesional, lesional &
normal, and non-lesional & normal.
The common genes among all the subgroups based
comparisons were identified. Supplementary Figures S1–S3
and S4–S6 depict the volcano plots displaying DEGs between
the defined subgroups of datasets E-GEOD-75343 and E-GEOD-
13355, respectively. The red dots in the volcano plots are the
identified DEGs. Supplementary Figures S7–S9 depict the
volcano plots displaying DEGs of E-GEOD-50790, E-GEOD-
41664 and E-GEOD-34248 datasets, respectively. The number of
identified DEGs from all the analyzed microarray datasets of
psoriasis are given in Table 2. The datasets of psoriasis were
compared for common genes by comparing the identified DEGs
from all five analyzed datasets. As a result of this comparison,
one common DEG, named s100a8, was identified. S100a8 is a
protein coding gene that mainly functions in inflammatory and
immune responses (47).
RNA-Seq Data Analysis of Psoriasis
Differentially expressed genes were identified between lesional &
non-lesional phenotypes in RNA-seq data analysis of psoriasis.
Two datasets of psoriasis were analyzed for RNA-seq analysis as
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shown in Table 1. The number of identified DEGs from these
two datasets is given in Table 3. From datasets E-GEOD-41745
and E-GEOD-67785, 153 and 833 DEGs were identified,
respectively. Supplementary Figures S10 and S11 depict the
volcano plots displaying DEGs between psoriatic lesional & non-
lesional phenotypes of datasets E-GEOD-41745 and E-GEOD-
67785, respectively. The datasets were then compared for
common genes by comparing the identified DEGs from both
the analyzed datasets. As a result of this comparison, 16 common
DEGs were identified. The common DEGs are given in Table 3.
This comparison also revealed that datasets E-GEOD-41745 and
E-GEOD-67785 have 137 and 817 unique identified DEGs, as
shown in Figure 2.
Microarray Data Analysis of cSCC
Studies have proposed the association of psoriasis with NMSC,
which include BCC and cSCC (12, 16). The chronic
inflammatory nature of psoriasis (12) and use of biologics (16)
might also increase the risk of cSCC in psoriasis patients.
Therefore, cSCC is analyzed in the current study to interpret
its association with psoriasis at the molecular level. A summary
of datasets analyzed for cSCC is provided in Table 1. Two
miRNA (E-GEOD-32868 and E-GEOD-34536) and one
mRNA datasets (E-GEOD-42677) of cSCC are analyzed in this
study. A total of six and 12 differentially expressed miRNAs were
identified from E-GEOD-32868 and E-GEOD-34536,
respectively (provided in Supplementary Tables S12 and S13).
The number of target genes of these differentially expressed
miRNAs is given in Table 2. The number of identified DEGs
from E-GEOD-42677 dataset is given in Table 2. The datasets E-
GEOD-32868 and E-GEOD-34536 are composed of two
phenotypes i.e., normal and cSCC. However, the dataset E-
GEOD-42677 is composed of three phenotypes i.e., normal,
cSCC-invasive, and cSCC-in situ. Therefore, the comparisons
for finding differential expression between all the possible
combinations of phenotypes within the dataset were performed
for this dataset. The comparisons were between: cSCC-invasive
& normal, cSCC-insitu & normal, and cSCC-invasive & cSCC-
insitu groups. Supplementary Figures S14–S16 show the
volcano plots of DEGs identified in the defined comparisons of
TABLE 2 | Number of identified DEGs/differentially expressed miRNAs of microarray datasets.
Sr. no. Dataset ID Disease RNA-type DEGs/differentially expressedmiRNAs
1 E-GEOD-
13355
Psoriasis mRNA 24 DEGs
2 E-GEOD-
75343
Psoriasis mRNA 25 DEGs
3 E-GEOD-
34248
Psoriasis mRNA 1041 DEGs
4 E-GEOD-
41664
Psoriasis mRNA 1250 DEGs
5 E-GEOD-
50790
Psoriasis mRNA 1425 DEGs
6 E-GEOD-
42677
cSCC mRNA 118 DEGs
7 E-GEOD-
32868
cSCC miRNA 6 miRNAs
• 884 target genes
8 E-GEOD-
34536
cSCC miRNA 12 miRNAs
• 1327 target genes
The target genes of identified differentially expressed miRNAs (of cSCC datasets E-GEOD-32868 and E-GEOD-34536) were extracted from miRWalk (38) database.
TABLE 3 | Number of identified and symbols of common DEGs of RNA-seq datasets.





153 16 PGM2, SOD2, SLC25A46,
SERPINB4,
DIO2, SPRR2B, IFI27, ATP12A,
2 E-GEOD-
67785
833 S100A7A, LCN2, IL20RB, S100A12,
TMPRSS11D, PI3, CD274 and IDH3A
cSCC Datasets
1 E-MTAB-5678 1693 26 ELOVL5, GJB6, EIF1, FABP5
2 GSE84293 349 ANKRD28, NT5C, GPATCH2, EGR1
ZFP36L2, SOX9, RUVBL1, MVD
TNS1, S100A8, COL3A1, POSTN
NFIB, ZFP36L1, GJB2, PRR34-AS1
RASD1, ADH1B, RHPN2, SREBF1
MAFF and INSIG1
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dataset E-GEOD-42677. Supplementary Figures S12 and S13
depict volcano plots displaying differentially expressed miRNAs
between cSCC and normal phenotypes, for datasets E-GEOD-
32868 and E-GEOD-34536, respectively. The datasets were
compared for common genes by comparing the identified
target genes of differentially expressed miRNAs with that of
mRNAs. For two miRNA datasets (E-GEOD-32868 & E-GEOD-
34536) 200 common DEGs were identified. However, no
common DEGs were identified between two miRNA datasets
and one mRNA dataset of cSCC.
RNA-Seq Data Analysis of cSCC
DEGs were identified between normal & cSCC phenotypes in RNA-
seq data analysis of cSCC. Two datasets of cSCC were analyzed for
RNA-seq analysis as shown in Table 1. The Table 3 shows the
number of identified DEGs from RNA-seq datasets of cSCC. From
datasets E-MTAB-5678 and GSE84293, 1693 and 349 DEGs were
identified, respectively. Supplementary Figures S17 and S18 depict
the volcano plots displaying DEGs between cSCC and normal
phenotypes of E-MTAB-5678 and GSE-84293, respectively. The
datasets were then compared for common genes by comparing the
identified DEGs from both the analyzed datasets. As a result of this
comparison, 26 common DEGs were obtained. The commonDEGs
are given in Table 3. This comparison also revealed that E-MTAB-
5678 has 1667 and GSE84293 has 323 unique identified DEGs, as
shown in Figure 2.
Pathway Analysis
Pathway analysis of DEGs of psoriasis and cSCC datasets
revealed the significant enrichment of these DEGs in various
pathways. The significant pathways (at p-value <= 0.05) of all the
analyzed datasets are provided in Supplementary Table 1. Out
of these significant pathways, IL-17 signaling pathway was found
common among the analyzed datasets of both psoriasis and
cSCC, as given in Table 4.
Quantitative Systems Biology
Simulation of the Model
The DEGs of psoriasis and cSCC were significantly enriched in
the IL-17 signaling pathway. A sub-section of complete IL-17
signaling pathway was modeled in Matlab for analyzing the
sensitivity of autoimmune pathology, neutrophil recruitment,
and immunity to extracellular pathogens towards DEGs. These
models for psoriasis and cSCC are shown in Figures 3 and 4,
respectively. The models were simulated by inserting the average
expression values (given in Table 5) of DEGs in psoriasis and
cSCC enriched in IL-17 signaling pathway. The simulation of
model unveiled the alterations in the concentrations of species
over time. The Figures 5A, B depict simulated processes of
autoimmune pathology, neutrophil recruitment, and immunity to
extracellular pathogens in psoriasis and cSCC, respectively. It is
cleared from Figures 5A, B that the rate of these biological processes
increases over time in both psoriasis and cSCC. However, the rate is
relatively higher in psoriasis. The peak value of these biological
processes in psoriasis is around 28 in 9.5 time units, whereas it is
observed to be around 21 in 10 time units in cSCC.
Sensitivity Analysis
Sensitivity analysis was performed to study the impact of the
species and reactions of the model on biological processes of
autoimmune pathology, neutrophil recruitment, and immunity
to extracellular pathogens. The Figures 6 and 7 depict the
sensitivity analysis of these biological processes in psoriasis and
cSCC, respectively. It is cleared from Figure 6 that the biological
processes are highly sensitive towards MAPKs, chemokines,
tissue remodeling genes, and AP-1 (FOSL1 and FOS genes) in
psoriasis, having sensitivity values greater than 1.5. Whereas in
cSCC, these biological processes are highly sensitive towards
MAPKs, AP-1 (FOSL1 and JUN genes), and TNF genes, having
sensitivity values greater than 1.5 as shown in Figure 7.
DISCUSSION
Psoriasis is one of the most common and chronic skin diseases
(1). It is characterized by rough scales on the skin. It could appear
on any part of the body and it affects both children and adults
(1). About 2-3% individuals are affected by psoriasis worldwide
(2), and the incidence rate of psoriasis is also observed to increase
with time (3). Association of psoriasis with other comorbidities,
A B
FIGURE 2 | (A) Comparative analysis of RNA-seq datasets of psoriasis. The analysis revealed 16 common DEGs between psoriasis datasets, and, 137 and 817
unique identified DEGs from datasets E-GEOD-41745 and E-GEOD-67785, respectively. (B) Comparative analysis of RNA-seq datasets of cSCC. The analysis
revealed 26 common DEGs between cSCC datasets, and, 1667 and 323 unique identified DEGs from datasets E-MTAB-5678 and GSE84293, respectively.
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FIGURE 3 | Model of IL-17 signaling pathway for psoriasis. The model is built as network of species (oval) and reactions (circle), which are connected by edges.
Species represent biological entities of the pathway, and are color coded. Dark blue color shows processes of autoimmune pathology, neutrophil recruitment, and
immunity to extracellular pathogens, yellow color depicts DEGs, green color shows DEG that are also acting as inhibitor, red color shows inhibitors, and sky-blue
color represents genes that are part of the pathway, however, not differentially expressed. The species MAPKs includes MAPK13 and MAPK14. Chemokines
includes CXCL1, CXCL2, CXCL5, CXCL8, CXCL10, CCL2, CCL7 and CCL20. The species Anti-microbial includes S100A7, S100A8, S100A9, and LCN2 genes.
Tissue remodeling includes MMP1 and MMP9 genes. C1, C2, C3 and AP-1 are complexes of genes. C1 includes Hsp90 and Act1. C2 includes TAB2, TAB3 and
TAK1 genes. C3 incorporates ANAPC5 and A20 genes, and AP-1 includes FOSL1 and FOS genes.
TABLE 4 | Common pathway of both the diseases. The DEGs of both the datasets of psoriasis and cSCC were enriched in IL-17 signaling pathway.
Sr. no. Pathway Psoriasis Datasets cSCC Datasets
1 IL-17 signaling pathway • E-GEOD-34248
• E-GEOD-41664
• E-GEOD-50790
• E-GEOD-13355 (lesional vs normal)
• E-GEOD-75343 (lesional vs normal)
• E-GEOD-13355 (non-lesional vs normal)
• E-GEOD-75343 (non-lesional vs normal)
• E-GEOD-67785
• E-GEOD-42677 (cSCC-insitu vs normal)
• E-GEOD-42677 (cSCC-invasive vs normal)
• GSE84293
FIGURE 4 | Model of IL-17 signaling pathway for cSCC. The model is built as network of species (oval) and reactions (circle), which are connected by edges.
Species represent biological entities of the pathway, and are color coded. Dark blue color shows processes of autoimmune pathology, neutrophil recruitment, and
immunity to extracellular pathogens, yellow color depicts DEGs, red color shows inhibitors, and sky-blue color represents genes that are part of the pathway,
however, not differentially expressed. The species MAPKs includes MAPK3, MAPK9, MAPK10, MAPK11, and MAPK14. Chemokines includes CXCL1, CXCL2,
CXCL8, and CCL20. The species Anti-microbial includes DEFB4A, DEFB4B, S100A7, S100A8, S100A9, and LCN2 genes. Tissue remodeling includes MMP1,
MMP3, MMP9, and MMP13 genes. C1, C2, C3 and AP-1 are complexes of genes. C1 includes Hsp90 and Act1. C2 includes TAB2, TAB3 and TAK1 genes. AP-1
includes FOSL1 and JUN genes.
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like cardiovascular diseases, diabetes, and metabolic syndrome,
has been observed (12). Studies have also revealed the possibility
of association of psoriasis with skin cancers, particularly non-
melanoma skin cancers (NMSC), which include basal cell
carcinoma (BCC) and cutaneous Squamous Cell Carcinoma
(cSCC) (12, 16). Hence, the second analyzed disease in this
study is cSCC. It is the second most prevalent nonmelanoma skin
cancer (19, 20) with potential to metastasize and recur in some
cases (19). Moreover, the incidence rate of cSCC is also
increasing annually (19, 20). Therefore, there exists a dire need
to analyze both the diseases at the molecular level to propose
potential biomarkers and common therapeutic targets.
This study was designed to interpret and compare the high-
throughput data of psoriasis and cSCC, aiming to reveal potential
biomarkers, common therapeutic targets, and the association
between the two diseases. Microarray and RNA-seq data analyses
were performed on the datasets of psoriasis and cSCC (given in
Table 1) to reveal the common and uncommon patterns. After
performing differential expression analysis, pathway analysis was
performed to analyze the disrupted pathways and their possible
relation with the disease. The common pathway between the
diseases was selected for further analysis. Afterwards, quantitative
systems biology was implemented, by using SimBiology application
in Matlab (30), to analyze the results at a holistic level. The
differential expression analysis of both the analyzed diseases
resulted in the identification of DEGs. Top 10 DEGs (along with
p-value and Log2FC) from all the analyzed datasets are provided in
Supplementary Tables S1–S18. The identified number of DEGs
frommicroarray data analysis are given in Table 2. The comparison
of microarray datasets of psoriasis resulted in one common DEG,
named S100A8. The significant role of S100A8 in prognosis of
psoriasis is also illustrated in the literature (48). The overexpression
of S100A8 causes keratinocyte proliferation and angiogenesis in
psoriatic skin (47, 49). The comparison of microarray datasets of
cSCC resulted in no common gene. The number of identified DEGs
from RNA-seq data analysis is given in Table 3. The comparison of
RNA-seq datasets resulted in 16 and 26 commonDEGs for psoriasis
and cSCC, respectively (given in Table 3). These common DEGs
could be proposed as potential biomarkers of the diseases. The
overall comparative analysis of identified DEGs from all the
analyzed datasets of both the diseases resulted in common DEGs
between the two diseases, as given in Table 6. These DEGs may
represent the potential biomarkers or therapeutic targets of psoriasis
and cSCC.
TABLE 5 | DEGs of psoriasis and cSCC significantly enriched in IL-17 signaling pathway.
Sr. no. Psoriasis DEGs Average Expressions cSCC DEGs Average Expressions
1 CXCL2 7.143566 SRSF1 11.30402
2 S100A8 13.03884 TNF 3.775442
3 S100A9 11.57422 S100A8 10.50457
4 LCN2 10.42698 ELAVL1 7.146701
5 CCL20 7.295939 TRAF6 5.351013
6 CXCL8 7.35222 LCN2 5.506456
7 FOSL1 6.836052 MAPK11 4.413777
8 IL1B 7.299115 CXCL3 4.455207
9 CXCL1 7.507195 DEFB4A 7.363343
10 S100A7 13.38452 JUN 9.363052
11 MMP1 7.214311 DEFB4B 7.363343
12 IFNG 5.405429 IKBKG 6.876049
13 CXCL10 8.052625 TRAF3IP2 3.874313
14 MAPK14 8.921881 FOSL1 4.520605
15 CCL2 9.811309 MAPK3 7.049278
16 MMP9 8.010812 S100A9 8.624269
17 IL17D 9.42729 IL1B 3.671266
18 MAPK13 11.11599 CCL20 4.261092
19 TAB3 5.693991 MAPK10 4.192857
20 IL17A 3.848178 MAPK9 4.239504
21 CCL7 4.973044 TRAF2 5.059843
22 IL17F 5.032107 S100A7 10.17163
23 IKBKE 6.796894 JUND 3.783349
24 IL17RE 8.205539 HSP90AA1 11.51992
25 ANAPC5 7.907747 MAPK14 5.104123









The average expression values were calculated for microarray datasets. The DEGs of psoriasis are of lesional vs non-lesional and lesional vs normal groups. The DEGs of cSCC are of cSC-
insitu vs normal and cSCC-invasive vs normal groups
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TABLE 6 | Potential biomarkers and therapeutic targets for psoriasis and cSCC.
Sr. no. Potential Therapeutic Targets Psoriasis Datasets cSCC Datasets




• E-GEOD- 13355 (lesional vs normal)
• E-GEOD-75343 (lesional vs normal)
• E-GEOD-13355 (lesional vs non-lesional)
• E-GEOD-75343 (lesional vs non-lesional)
• E-GEOD-42677 (cSCC-insitu vs normal)
• E-GEOD-42677 (cSCC-invasive vs normal)
• E-MTAB-5678
• GSE84293
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Pathway analysis of DEGs of psoriasis and cSCC revealed the
enrichment of these DEGs in various pathways (provided in
Supplementary Table 1). The current study has proposed one
common significant pathway, IL-17 signaling pathway, based on
the enrichment of DEGs of both the diseases in that pathway
(given in Table 4). Genome-wide association and other genetic
studies have clearly linked multiple IL-17–related genes to
psoriasis pathogenesis. Psoriasis is one of the most typical IL-
17A-driven human diseases (50). The expression of various IL-
17 signaling pathway genes elevated in psoriatic lesional tissue
compared with non-lesional tissue (51). The significance of IL-17
signaling pathway in the prognosis of cSCC is also illustrated in
the literature, as the disrupted IL-17 pathway promotes tumor
development by activating cytokines production (52).
IL-17 signaling pathway was selected for further analysis, as it
was common in both psoriasis and cSCC datasets. IL-17
signaling play a critical role in tumor microenvironment by
facilitating tumor formation and metastasis (53). Quantitative
systems biology was implemented to analyze the results at a
holistic level. A sub-section of complete IL-17 pathway was
modeled by using SimBiology application in Matlab (30). The
average expressions values of DEGs that were present in the
pathway were calculated for microarray datasets of psoriasis and
cSCC, as given in Table 5. The model was then simulated by
adding the average expression values to the species (genes) as
initial state values. The biological processes being analyzed in the
model were autoimmune pathology, neutrophil recruitment, and
immunity to extracellular pathogens. Autoimmunity is defined
as when the immune system of the body becomes hyperactive
and acts against self-antigen, thus, resulting in tissue damage
(54). Cancer is often associated with autoimmunity.
Autoimmune disorders like scleroderma and myositis might
increase the risk of cancer (55). Neutrophils are the type of
leukocytes that protect the body in state of infections and
inflammation (56). Clinical evidence has revealed that tumor
associated neutrophils (TANs) might play a critical role in tumor
progression. Adaptive immune system of the host becomes
activated by exhibiting particular responses to extracellular
pathogens (57). The clinical evidence has suggested that
abnormal adaptive immunity lead to tumor cell proliferation
by inducing immunosuppression (58).
The Figures 5A, B depict simulated processes of autoimmune
pathology, neutrophil recruitment, and immunity to
extracellular pathogens in psoriasis and cSCC, respectively. It is
cleared from Figures 5A, B that the rate of these biological
processes increases over time in both psoriasis and cSCC.
However, the rate is relatively higher in psoriasis. The peak
value of these biological processes in psoriasis is around 28 in 9.5
time units, whereas it is observed to be around 21 in 10 time units
in cSCC.
After simulation of the model, sensitivity analysis was
performed to analyze the response of the biological processes
to model quantities (DEGs and genes). The sensitivity analysis
revealed that autoimmune pathology, neutrophil recruitment,
and immunity to extracellular pathogens are highly sensitive
towards MAPKs, chemokines, tissue remodeling genes, and AP-
1 (FOSL1 and FOS genes) in psoriasis, having sensitivity values
greater than 1.5 Figure 6. It indicates that the slight changes in
these genes profoundly affect the biological processes. These
results are also consistent with the literature. Disrupted signaling
pathways are associated with the complex pathogenesis of
psoriasis, particularly, the possible pathogenic role of disrupted
MAPK signaling in the development of psoriasis (59, 60).
Chemokines and chemokine receptors are involved in the
pathogenesis of psoriasis by facilitating the trafficking of T-cells
in psoriasis (61). Therefore, targeting chemokines in psoriasis
would result in therapeutic effect and improved treatment for
psoriasis (61, 62). Tissue remodeling genes (MMPs) contribute
to the pathogenesis of psoriasis by stimulating angiogenesis and
intrusion of immune cells in the dermal tissue (63). AP-1 (the
A B
FIGURE 5 | Simulated graphs of autoimmune pathology, neutrophil recruitment, and immunity to extracellular pathogens. The x-axis represents time, whereas y-axis
depicts concentration. (A) Simulated graph of autoimmune pathology, neutrophil recruitment, and immunity to extracellular pathogens in psoriasis. In psoriasis,
activation of autoimmune pathology, neutrophil recruitment, and immunity to extracellular pathogens start immediately and reach their peak value around 28 in 9.5
time units and become constant after it. (B) Simulated graph of autoimmune pathology, neutrophil recruitment, and immunity to extracellular pathogens in cSCC.
Autoimmune pathology, neutrophil recruitment, and immunity to extracellular pathogens activate immediately in cSCC and reach their peak value around 21 in 10
time units.
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transcription factor activator protein 1) functions in cell
proliferation. However, the binding ability of AP-1 is highly
damaged in psoriatic lesional skin (64), thus genes for AP-1 are
significant in pathogenesis of psoriasis and proposed as
candidate target genes (65).
Whereas the sensitivity analysis of cSCC revealed that the
biological processes are highly sensitive towards MAPKs, AP-1
(FOSL1 and JUN genes), and TNF genes, having sensitivity
values greater than 1.5 as shown in Figure 7. The slight
changes in these genes profoundly affect the biological
processes. These results are also consistent with the literature.
Dysregulated MAPK signaling by high levels of HMG-1 protein
stimulates metastasis in cSCC (66). Dysregulation in the
expression of the genes for AP-1 (the transcription factor
FIGURE 6 | Sensitivity analysis of Autoimmune pathology (AP), neutrophil recruitment (NR), and immunity to extracellular pathogens (IEP) in psoriasis. The x-axis
represents input species (genes), whereas y-axis depicts sensitivity of AP, NR and IEP. The high influence of MAPKs, chemokines, tissue remodeling genes, and AP-
1 is observed in AP, NR and IEP. It indicates that AP, NR and IEP are highly sensitive towards these genes, having sensitivity values greater than 1.5.
FIGURE 7 | Sensitivity analysis of Autoimmune pathology (AP), neutrophil recruitment (NR), and immunity to extracellular pathogens (IEP) in cSCC. The x-axis
represents input species (genes), whereas y-axis depicts sensitivity of AP, NR and IEP. The high influence of MAPKs, AP-1, and TNF is observed in AP, NR and IEP.
It indicates that AP, NR and IEP are highly sensitive towards these genes, having sensitivity values greater than 1.5.
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activator protein 1) promote cancer development as AP-1 factors
are involved in keratinocyte proliferation of skin (67). TNF
(Tumor necrosis factor) is a proinflammatory cytokine that
mainly functions in cell proliferation, differentiation, and
death, hence plays an important role in carcinogenesis (68).
Sensitivity analysis of the biological processes of both
psoriasis and cSCC revealed MAPKs and genes for AP-1 as
significant genes. Slight change in these genes would greatly
impact autoimmune pathology, neutrophil recruitment, and
immunity to extracellular pathogens. Therefore, consistent
with the discussion we propose that MAPKs (MAPK13 and
MAPK14) and genes for AP-1 (FOSL1 and FOS) identified from
sensitivity analysis of psoriasis are significant genes that might
lead psoriasis towards cancer.
CONCLUSION
In the current study, the integrated data analysis of microarray
and RNA-seq was performed to reveal common patterns
between psoriasis and cSCC. The differential expression
analysis of both the diseases resulted in common DEGs, which
are proposed as potential biomarkers and therapeutic targets for
psoriasis and cSCC. IL-17 signaling pathway is identified as
common significant pathway as DEGs of both the diseases were
enriched in that pathway. IL-17 was further studied, and
sensitivity analysis was performed that resulted in the
identification of significant genes in psoriasis, that might lead
psoriasis towards cancer. These significant genes are MAPKs
(MAPK13 and MAPK14) and genes for AP-1 (FOSL1 and FOS).
These genes should be further investigated at experimental level
for validating their roles in the transfer of psoriatic condition
to cSCC.
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